Clinical Trial Update: A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study comparing once-daily versus twice-daily arformoterol in chronic obstructive pulmonary disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Arformoterol (Brovana) (arformoterol)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: COPD | Phase 2 | Status: COMPLETED